COHERUS ONCOLOGY INC (CHRS) Stock Fundamental Analysis

NASDAQ:CHRS • US19249H1032

1.68 USD
+0.01 (+0.6%)
At close: Feb 25, 2026
1.69 USD
+0.01 (+0.6%)
After Hours: 2/25/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

CHRS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. CHRS may be in some trouble as it scores bad on both profitability and health. CHRS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year CHRS has reported negative net income.
  • CHRS had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: CHRS reported negative net income in multiple years.
  • CHRS had negative operating cash flow in 4 of the past 5 years.
CHRS Yearly Net Income VS EBIT VS OCF VS FCFCHRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 30.00%, CHRS belongs to the top of the industry, outperforming 98.27% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 176.56%, CHRS belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
Industry RankSector Rank
ROA 30%
ROE 176.56%
ROIC N/A
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRS Yearly ROA, ROE, ROICCHRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

1.3 Margins

  • The Profit Margin of CHRS (185.44%) is better than 98.85% of its industry peers.
  • In the last couple of years the Profit Margin of CHRS has declined.
  • Looking at the Gross Margin, with a value of 47.79%, CHRS is in the better half of the industry, outperforming 75.43% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CHRS has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 185.44%
GM 47.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
CHRS Yearly Profit, Operating, Gross MarginsCHRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CHRS has been increased compared to 1 year ago.
  • Compared to 5 years ago, CHRS has more shares outstanding
  • Compared to 1 year ago, CHRS has an improved debt to assets ratio.
CHRS Yearly Shares OutstandingCHRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CHRS Yearly Total Debt VS Total AssetsCHRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -4.09, we must say that CHRS is in the distress zone and has some risk of bankruptcy.
  • CHRS has a Altman-Z score of -4.09. This is comparable to the rest of the industry: CHRS outperforms 42.42% of its industry peers.
  • CHRS has a Debt/Equity ratio of 0.58. This is a neutral value indicating CHRS is somewhat dependend on debt financing.
  • CHRS has a worse Debt to Equity ratio (0.58) than 70.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -4.09
ROIC/WACCN/A
WACC8.56%
CHRS Yearly LT Debt VS Equity VS FCFCHRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 1.24 indicates that CHRS should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.24, CHRS is not doing good in the industry: 83.49% of the companies in the same industry are doing better.
  • CHRS has a Quick Ratio of 1.23. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.23, CHRS is not doing good in the industry: 82.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.24
Quick Ratio 1.23
CHRS Yearly Current Assets VS Current LiabilitesCHRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for CHRS have decreased strongly by -19.27% in the last year.
  • CHRS shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -27.39% yearly.
  • CHRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -72.54%.
  • The Revenue has been decreasing by -5.60% on average over the past years.
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%

3.2 Future

  • Based on estimates for the next years, CHRS will show a decrease in Earnings Per Share. The EPS will decrease by -4.36% on average per year.
  • Based on estimates for the next years, CHRS will show a small growth in Revenue. The Revenue will grow by 3.09% on average per year.
EPS Next Y-95.39%
EPS Next 2Y-14.02%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue Next Year-83.13%
Revenue Next 2Y-44.95%
Revenue Next 3Y-26.95%
Revenue Next 5Y3.09%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CHRS Yearly Revenue VS EstimatesCHRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CHRS Yearly EPS VS EstimatesCHRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CHRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRS Price Earnings VS Forward Price EarningsCHRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRS Per share dataCHRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as CHRS's earnings are expected to decrease with -4.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.02%
EPS Next 3Y-4.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CHRS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COHERUS ONCOLOGY INC

NASDAQ:CHRS (2/25/2026, 8:00:01 PM)

After market: 1.69 +0.01 (+0.6%)

1.68

+0.01 (+0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-09
Inst Owners42.21%
Inst Owner Change-1.47%
Ins Owners6.08%
Ins Owner Change-0.1%
Market Cap203.06M
Revenue(TTM)83.57M
Net Income(TTM)154.97M
Analysts83.33
Price Target5.78 (244.05%)
Short Float %31.14%
Short Ratio13.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.95%
Min EPS beat(2)-12.36%
Max EPS beat(2)0.45%
EPS beat(4)1
Avg EPS beat(4)-42.18%
Min EPS beat(4)-108.91%
Max EPS beat(4)0.45%
EPS beat(8)3
Avg EPS beat(8)-57.9%
EPS beat(12)6
Avg EPS beat(12)-36.26%
EPS beat(16)8
Avg EPS beat(16)-35.21%
Revenue beat(2)0
Avg Revenue beat(2)-8.12%
Min Revenue beat(2)-15.42%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-22.58%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)12.3%
Revenue beat(8)3
Avg Revenue beat(8)-10.27%
Revenue beat(12)4
Avg Revenue beat(12)-11.09%
Revenue beat(16)4
Avg Revenue beat(16)-11.88%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.28%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-8.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.43
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB 5.3
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.69
BVpS0.73
TBVpS0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 30%
ROE 176.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 185.44%
GM 47.79%
FCFM N/A
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.24
Quick Ratio 1.23
Altman-Z -4.09
F-Score4
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.27%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-3200%
EPS Next Y-95.39%
EPS Next 2Y-14.02%
EPS Next 3Y-4.33%
EPS Next 5Y-4.36%
Revenue 1Y (TTM)-72.54%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-83.65%
Revenue Next Year-83.13%
Revenue Next 2Y-44.95%
Revenue Next 3Y-26.95%
Revenue Next 5Y3.09%
EBIT growth 1Y-33.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.59%
EBIT Next 3Y12.47%
EBIT Next 5Y7.38%
FCF growth 1Y65.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.55%
OCF growth 3YN/A
OCF growth 5YN/A

COHERUS ONCOLOGY INC / CHRS FAQ

What is the ChartMill fundamental rating of COHERUS ONCOLOGY INC (CHRS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CHRS.


What is the valuation status of COHERUS ONCOLOGY INC (CHRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to COHERUS ONCOLOGY INC (CHRS). This can be considered as Overvalued.


Can you provide the profitability details for COHERUS ONCOLOGY INC?

COHERUS ONCOLOGY INC (CHRS) has a profitability rating of 3 / 10.


What is the expected EPS growth for COHERUS ONCOLOGY INC (CHRS) stock?

The Earnings per Share (EPS) of COHERUS ONCOLOGY INC (CHRS) is expected to decline by -95.39% in the next year.